Ipsen

Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Mass Device
Ipsen
gastroenteropancreatic neuroendocrine tumor
Somatuline
Flag link:
Sanofi Sells 5 Over-the-Counter Drugs for $88M
Sanofi Sells 5 Over-the-Counter Drugs for $88M
Investopedia
Sanofi
OTC
M&A
Ipsen
Flag link:
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
Yahoo/Reuters
Ipsen
France
Merrimack Pharmaceuticals
pancreatic cancer
Onivyde
Flag link:
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Flag link:
Ipsen to Step Up Deal-Making, Scout for New Cancer Products
Ipsen to Step Up Deal-Making, Scout for New Cancer Products
Bloomberg
Ipsen
M&A
oncology
Flag link:
Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push
Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push
Fierce Pharma Marketing
Ipsen
Somatuline
hirings
drug launches
Flag link:
Nestle’s Galderma Deepens Ipsen Alliance for Wrinkle Smoother
Nestle’s Galderma Deepens Ipsen Alliance for Wrinkle Smoother
Bloomberg
Nestle
Galderma
Ipsen
Dysport
Azzalure
Flag link:
China Drug Probe Leads to Tougher Market, Ipsen CEO Says
China Drug Probe Leads to Tougher Market, Ipsen CEO Says
Bloomberg
China
Ipsen
Flag link:
Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech
Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech
Fierce Biotech
Baxter International
Ipsen
hemophilia
Flag link:
Roche Said to Return Diabetes Drug Rights to Ipsen
Roche Said to Return Diabetes Drug Rights to Ipsen
Bloomberg
Ipsen
Roche
diabetes
taspoglutide
Flag link:
The Top 10 Phase III Failures of 2010
The Top 10 Phase III Failures of 2010
Fierce Biotech
clinical trials
dimebon
Medivation
Pfizer
ocrelizumab
Roche
rheumatoid arthritis
taspoglutide
diabetes
Ipsen
semagacestat
Eli Lilly
ASA404
Antisoma
Novartis
Novelos Therapeutics
AstraZeneca
zibotentan
vicriviroc
Merck
Recentin
Vical
Sanofi
Flag link:
Roche’s Taspoglutide for Diabetes Meets Goal, Ipsen Says
Roche’s Taspoglutide for Diabetes Meets Goal, Ipsen Says
Bloomberg
Ipsen
Roche
diabetes
taspoglutide
Flag link:
FDA Warns Researcher For Promoting A Drug
FDA Warns Researcher For Promoting A Drug
Pharmalot
FDA
Reloxin
Ipsen
Dysport
Flag link:
Ipsen Buys Inspiration Stake in Hemophilia Alliance
Ipsen Buys Inspiration Stake in Hemophilia Alliance
Bloomberg
hemophilia
Ipsen
Inspiration
M&A
Flag link:
Ipsen, Roche’s Taspoglutide Matches Sanofi’s Lantus
Ipsen, Roche’s Taspoglutide Matches Sanofi’s Lantus
Bloomberg
Lantus
diabetes
Ipsen
Roche
taspoglutide
Flag link:
Roche's New Diabetes Drug Works Better Than Byetta
Roche's New Diabetes Drug Works Better Than Byetta
WSJ Online
Byetta
diabetes
Roche
Ipsen
taspoglutide
Flag link:
Ipsen Afflicted by Too Many Drugs, Bucks Trend Infecting Others
Ipsen Afflicted by Too Many Drugs, Bucks Trend Infecting Others
Bloomberg
Ipsen
Allergan
Botox
Flag link:
U.K. Approves a Botox Rival
U.K. Approves a Botox Rival
WSJ Online
Allergan
Botox
Ipsen
Azzalure
Medicis
UK
Flag link: